{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Mexico Diagnostics & Research news", "home_page_url": "https://sharemaestro.com/newsreel/mx/healthcare/diagnostics-research/", "feed_url": "https://sharemaestro.com/newsreel/mx/healthcare/diagnostics-research/feed.json", "description": "Latest Diagnostics & Research company headlines from Mexico, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:2dd4be49feba281b049e08a85747f7bdd52c55d23b81c7a35a04371f8a8f139b", "url": "https://finance.yahoo.com/healthcare/articles/strong-q2-2026-results-cardiac-021011441.html", "external_url": "https://finance.yahoo.com/healthcare/articles/strong-q2-2026-results-cardiac-021011441.html", "title": "Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?", "content_text": "IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We'll now examine how the new Catalyst proBNP Test and raised 2026 guidance may reshape IDEXX's broader investment narrative. Capitalize on the AI infrastructure su", "date_published": "2026-08-13T02:10:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IDXX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IDXX", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/f778ff6f-21d3-4bb3-affa-e4d719df5175/"}]}}, {"id": "source:4de41d510eb6b85ba6b7bab47e5d874ee9668bafd394ff2f37adc57dcbc6d752", "url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "external_url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "title": "Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)", "content_text": "LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we'll examine how the raised 2026 growth outlook and manufacturing investments may influence LivaNova's existing investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. LivaNova Investment Narrative Recap To own LivaNova, you need to believe its cardiopulmonary and neuromodulation franchises can keep converting procedure demand into profitable, recurring revenue while managing pricing and reimbursement pressure. The Q2 2026 beat and higher revenue outlook support the near term growth catalyst in cardiopulmonary, but also highlight the key risk that higher manufacturing and IT spending, if not carefully controlled, could squeeze margins even as volumes rise. The long term oxygenator supply agreement with Thermo Fisher Scientific is especially relevant here, because it directly addresses prior supply constraints in cardiopulmonary consumables. By securing critical components and supporting capacity expansion, LivaNova is trying to align its manufacturing footprint with the heightened 2026 guidance, which may help underpin the cardiopulmonary growth story while leaving execution and supplier dependence as issues to watch. Yet even with stronger guidance, investors should be aware that higher spending on capacity and IT could still pressure margins if... Read the full narrative on LivaNova (it's free!) LivaNova's narrative projects $1.8 billion revenue and $220.8 million earnings by 2029. Uncover how LivaNova's forecasts yield a $84.80 fair value, a 5% upside to its current price. Exploring Other PerspectivesLIVN 1-Year Stock Price Chart Some of the lowest ranked analysts were assuming only about 5 percent annual revenue growth and US$177.7 million in earnings by 2029, so compared with today's stronger guidance and supply agreement, their view reflects a far more cautious stance on supplier bottlenecks and margin pressure that you may want to compare with your own expectations. Explore 2 other fair value estimates on LivaNova - why the stock might be worth just $84.80! Story Continues The Verdict Is Yours Don't just follow the ticker - dig into the data and build a conviction that's truly your own. A great starting point for your LivaNova research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance. No Opportunity In LivaNova? These stocks are moving-our analysis flagged them today. Act fast before the price catches up: Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution. The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. Outshine the giants: these 16 early-stage AI stocks could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven", "date_published": "2026-08-12T23:16:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:514e128ebb8254b2e7833258dba6fdd75fb5811bfb18edc60a79a42420c9a8e5", "url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "title": "LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a year to date share price return of 33.21%. The 1 year total shareholder return of 52.24% suggests momentum has been building over a longer stretch. If you are looking for more ideas in healthcare technology, this is a good moment to widen the search with 43 healthcare AI stocks Bulls argue that LivaNova's guidance lift and profitability reset justify a rerating. Bears see a hot chart and guidance upgrade as already reflected in the price. Do current valuation markers support the optimism or the caution? Most Popular Narrative: 4.7% Undervalued LivaNova's most followed narrative sets a fair value of $84.80 against the last close at $80.78, which points to a modest valuation gap that hinges on how durable its cardiopulmonary and neuromodulation growth proves to be over time. The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, the launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins. Read the complete narrative. Want to see what sits behind that confidence in LivaNova's therapies? The fair value leans on steady top line progress, margin uplift and a richer earnings mix. Curious which specific revenue path and profitability targets underpin that 4.7% gap? The full narrative lays out the concrete milestones that have to fall into place. Result: Fair Value of $84.80 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, LivaNova's story can change quickly if reimbursement tightens or if key neuromodulation and sleep apnea launches face regulatory or adoption setbacks. Find out about the key risks to this LivaNova narrative. Next Steps Story Continues With LivaNova pulling in both optimism and concern, it makes sense to check the underlying data yourself and move quickly to form your own stance by weighing its 4 key rewards and 1 important warning sign Looking for more investment ideas beyond LivaNova? If you want a broader watchlist alongside LivaNova, use the Simply Wall Street Screener to quickly spot other stocks that might fit your style and goals. Target potential bargains early by scanning the 49 high quality undervalued stocks to see which stocks currently trade below their assessed value. Focus on resilience by reviewing the 84 resilient stocks with low risk scores so you can concentrate on companies with lower overall risk scores. Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems to see which under-the-radar stocks have strong fundamentals before others catch on. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in", "date_published": "2026-08-12T22:09:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:99556c19d5e3732cd8459b95bce092480b6f9f809a23b02a2c93fd6ee13b71a2", "url": "https://finance.yahoo.com/markets/stocks/articles/iqv-stock-gains-42-3-130900530.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/iqv-stock-gains-42-3-130900530.html", "title": "IQV Stock Gains 42% in 3 Months: Here's What You Should Know", "content_text": "IQVIA Holdings Inc. IQV stock has rallied over the past three months. The company's shares have jumped 41.5%, outperforming the industry's 17.2% growth and the Zacks S&P 500 Composite's 3.4% uptick. 3-Month Share Price PerformanceZacks Investment Research Image Source: Zacks Investment Research Let us delve into the factors that have contributed to the company's outperformance. Record Net Bookings & Solid Backlogs IQVIA's net new bookings were $3.2 billion for research and development solutions (R&DS) in the second quarter of 2026. It marked 19% year-over-year growth, resulting in a book-to-bi", "date_published": "2026-08-12T13:09:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IQV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IQV", "name": "IQVIA Holdings Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1923edc2-ce9d-4226-9982-745e38a79bad/"}]}}, {"id": "source:029b930f20a105a95eaa12cd975b6a874a0df5533dd2b17096e2a683ed2b555d", "url": "https://finance.yahoo.com/healthcare/articles/astorg-completes-acquisition-microbiology-business-121000815.html", "external_url": "https://finance.yahoo.com/healthcare/articles/astorg-completes-acquisition-microbiology-business-121000815.html", "title": "Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist", "content_text": "The transaction establishes an independent company, with the Microbiology business providing the foundation of a global microbiology diagnostics platform serving the clinical, food safety and pharmaceutical markets. The investment reflects Astorg's focused healthcare strategy and distinctive approach to complex transactions, combining deep sector expertise, and a strong track record of operational value creation. Dirk Bontridder has been appointed Chief Executive Officer to lead the company through its next stage of growth, in partnership with Astorg. LUXEMBOURG & NEW YORK & PARIS, August 12, 2026--(BUSINESS WIRE)--Astorg, a leading pan-European private equity firm, today announced the successful completion of its acquisition of the global microbiology business from Thermo Fisher Scientific. The business will now operate as an independent company under the leadership of Chief Executive Officer Dirk Bontridder and will launch under a new corporate brand later in 2026. The Microbiology business is a global provider of diagnostic consumables and equipment used in microbiological testing across clinical, food safety, and pharmaceutical applications. The business serves more than 15,000 customers across over 100 countries and employs approximately 2,400 employees across 13 manufacturing and R&D sites around the world. Commenting on the completion, Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, said: \"This is precisely the type of complex opportunity where Astorg can make a difference, combining deep healthcare expertise, an entrepreneurial and hands-on partnership model, and a strong track record of value creation across the companies we back.\" Olivier Lieven, Partner at Astorg, added: \"We are delighted to welcome Dirk and look forward to working with him and the management team to deliver the company's next phase of growth, accelerate innovation and strengthen its global position.\" Dirk Bontridder, Chief Executive Officer, concluded: \"This is a unique journey to create an independent global microbiology diagnostics company with an exceptional portfolio, talented teams and a long-standing reputation for quality, scientific excellence and customer service. I look forward to working with colleagues around the world and with Astorg to build on these strengths, continue delivering the products, service and innovation that our customers rely on, and introduce our new brand in due course as we begin this next chapter.\" Dirk brings more than 25 years of international leadership experience across life sciences, diagnostics and industrial technology. Most recently, he served as Chief Executive Officer of PerkinElmer, where he led the company's transformation into a focused global provider of analytical and laboratory solutions. He previously served as Chief Executive Officer of Reynaers Group and as Group Executive Vice President BioPharma Services & Clinical Diagnostics at Eurofins Scientific, one of the world's leading life sciences companies. Dirk began his career as a management consultant at McKinsey & Company. Story Continues About Astorg Astorg is a leading pan-European private equity firm with over \u20ac24 billion of assets under management. Astorg is a multi-specialist investor with deep expertise in healthcare, technology and business services. Within healthcare, Astorg concentrates on a narrow set of subsectors: pharmaceutical services and technology, MedTech and MedTech services, life science tools, and diagnostics. Enjoying a distinct entrepreneurial culture, an engaged shareholder perspective and a lean decision making body, Astorg works with founders, entrepreneurs and management teams to acquire premium international B2B businesses, providing them with strategic guidance, governance and capital to enhance their strategic positioning and achieve their financial objectives. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan. For more information about Astorg:", "date_published": "2026-08-12T12:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:688dd6155a7cb88c81afaf3dfbc5f3ff71c8943fffdd208b3d801f90606caafe", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-completes-sale-120000581.html", "external_url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-completes-sale-120000581.html", "title": "Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg", "content_text": "WALTHAM, Mass., August 12, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, forconsideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing. The business generated $645 million in revenue in 2025 and was part of Thermo Fisher's Specialty Diagnostics segment. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260812171039/en/ Contacts Media Contact Information: Sandy Pound Thermo Fisher Scientific Phone: 781-622-1223 E-mail: sandy.pound@thermofisher.com Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1356 E-mail: rafael.tejada@thermofisher.com View Comments", "date_published": "2026-08-12T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:d7ffec6e6848b736b4a9bdaa99baad8cd5c62764060ba7d18bbb63b3adaa648a", "url": "https://finance.yahoo.com/healthcare/articles/following-hamamatsus-rebranding-nkt-photonics-112000673.html", "external_url": "https://finance.yahoo.com/healthcare/articles/following-hamamatsus-rebranding-nkt-photonics-112000673.html", "title": "Following Hamamatsu's Rebranding of NKT Photonics to Drive Laser Innovation, New Biophotonics Market Overview Maps Strategic Growth Through 2030", "content_text": "Company Logo Accelerating momentum across major industry heavyweights\u2014highlighted by Thermo Fisher Scientific's Q2 2026 revenue beat, Hamamatsu Photonics' launch of its dedicated Lasers & Fibers Business Unit, and BD's $4.98 billion Q3 performance\u2014is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This report provides an in-depth analysis of key technological advancements, regional market shares, and competitive strategies across the global biophotonics sector. Biophotonics MarketBiophotonics Market Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The \"Biophotonics - A Global Market Overview\" has been added to ResearchAndMarkets.com's offering. Global Biophotonics Market to Reach US$123 Billion by 2032, Driven by Advanced Imaging and Medical Diagnostics The global biophotonics market is projected to expand from US$70.4 billion in 2025 to US$123 billion by 2032, registering a compound annual growth rate (CAGR) of 8.3% during the forecast period. Growth is supported by the rising adoption of non-invasive diagnostic systems, increasing demand for precision medicine, advances in optical imaging, and broader use of light-based technologies across healthcare, life sciences, research, and industrial applications. Advanced imaging systems, molecular diagnostics, biosensors, and continued innovation in in-vivo and in-vitro technologies are among the primary factors strengthening the global biophotonics market outlook. Imaging remained the largest application segment in 2025, while medical diagnostics accounted for the leading share of end-use revenue. Non-medical applications are expected to deliver the fastest growth through 2032 as biophotonic technologies gain traction in environmental monitoring, agriculture, food analysis, and industrial testing. Regional Biophotonics Market Outlook North America led the global biophotonics market in 2025, accounting for 38.7% of total revenue. The region's leadership reflects its established healthcare infrastructure, substantial research and development activity, high adoption of advanced diagnostic technologies, and strong presence of leading market participants. Europe ranked as the second-largest regional market, supported by continued investment in medical research, optical technologies, and life sciences. Asia-Pacific is forecast to record the fastest regional growth, with a CAGR of 10% from 2025 to 2032. The regional market is projected to reach US$32.6 billion by 2032, representing 26.5% of global revenue. Expanding healthcare infrastructure, growing research investment, rising healthcare expenditure, and increasing adoption of advanced medical imaging and diagnostic platforms are expected to support this expansion. Story Continues Market Analysis by Application and Sub-Type Imaging was the largest biophotonics application segment in 2025, generating US$39 billion, followed by analytics and sensing. See-through imaging led the imaging category with revenue of US$16.6 billion. Surface imaging is projected to be the fastest-growing imaging sub-type, advancing at a CAGR of 9.3% through 2032. Within analytics and sensing, molecular spectroscopy held a dominant 64.3% share in 2025. Biosensors are forecast to be the fastest-growing sub-type as demand increases for rapid, sensitive, and minimally invasive testing across clinical diagnostics, pharmaceutical development, environmental analysis, and biological research. In processing and curing, light therapy accounted for 82.5% of segment revenue and is expected to retain its leading position during the forecast period. Market Analysis by Technology In-vivo technology was the leading segment in 2025, valued at US$39.5 billion and accounting for 56.2% of global biophotonics market revenue. The segment is also expected to post the fastest technology-based growth, registering a CAGR of 8.5% and reaching US$70 billion by 2032. Demand is being reinforced by advances in real-time imaging, disease detection, surgical guidance, phys", "date_published": "2026-08-12T11:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:e193ce5d09ef17f40a944d36aef73475a80d32e58dad88be4a4684e491af8b06", "url": "https://seekingalpha.com/news/4631287-sp500-nasdaq-dow-jones-outlook-stock-market-cpi?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631287-sp500-nasdaq-dow-jones-outlook-stock-market-cpi?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Stock futures little changed as traders await inflation report", "content_text": "[Wall Street-Street Sign] P_Wei/E+ via Getty Images Stock index futures were muted on Wednesday as traders turned their attention to a closely watched consumer inflation report that could offer fresh clues on the Federal Reserve's policy path. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.01%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.12%, and Nasdaq futures (US100:IND) +0.18%. The consumer price index is seen up a more routine 0.1% month-over-month and 0.2% on a core basis in June, with annual increases of 3.4% and 2.4%. Among S&P 500 stocks, Super Micro Co", "date_published": "2026-08-12T08:14:56+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "A"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "A", "name": "Agilent Technologies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/032b3275-87e7-4f5e-9f70-0407ffa83c1d/"}]}}, {"id": "source:1bf1a09d8e5ed239af1711d1be1d1d1ea675858affeadb586e3289c88f63c03f", "url": "https://finance.yahoo.com/healthcare/articles/vitiligo-registry-move-needle-thermo-212006914.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vitiligo-registry-move-needle-thermo-212006914.html", "title": "Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?", "content_text": "Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter growth engine: the real-world data business tucked inside its lab-services empire, far from the instruments most investors picture when they hear the name.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Growth Machine Built On Deals Thermo Fisher has leaned on acquisitions to expand for years, buying smaller companies and then plugging them into its own sales and distribution network. The pattern shows up in the numbers. In 2025, the company posted revenue of $44.6 billion, up 4%, and EPS of $17.74, up 7%, with the life sciences solutions segment growing revenue 8% to $10.4 billion on stronger bioproduction demand. Thermo Fisher has kept the deal machine running, agreeing to buy Clario Holdings, which handles endpoint data for clinical trials, in an $8.8 billion deal, on top of last year's $4 billion purchase of Solventum's filtration and purification unit. The new vitiligo registry fits that same playbook of adding data and evidence services around its core business. It enrolls adolescents and adults aged 12 and older with dermatologist-confirmed nonsegmental vitiligo across the US, collecting both clinician and patient-reported outcomes to fill gaps around treatment durability and sequencing for therapies including JAK inhibitors. That kind of longitudinal evidence is exactly what drugmakers pay for once a therapy reaches the market, and it extends CorEvitas' existing autoimmune and dermatology registry portfolio into a new disease area. Bear Case: A Premium Price For Modest Growth The company's own guidance, excluding Clario, calls for 2026 revenue of $46.3 billion to $47.2 billion, roughly 5% growth at the midpoint, a pace that looks unremarkable next to the size of the checks being written for acquisitions. Shares are down more than 15% this year even as Thermo Fisher keeps adding debt-funded deals to the balance sheet, and a single disease registry covering nonsegmental vitiligo is a small addition next to a company generating tens of billions in annual revenue. The dividend yield remains thin at around 0.36%, so income investors are not being paid much to wait out the acquisition strategy, and every new deal raises the question of whether integration keeps pace with the dealmaking itself. Story Continues What The Market Is Pricing In Hedge fund ownership rose to 115 funds last quarter from 113 the quarter before, a modest tick toward accumulation. Short interest sits at just 1.43% of the float, showing little organized bearish positioning. Shares trade at a forward price-to-earnings ratio of 23.87, a premium that assumes the acquisition-fueled growth story keeps working. Rising fund ownership paired with light short interest suggests the market is not particularly worried about the deal-heavy approach right now. Where This Leaves Investors The vitiligo registry itself will not move Thermo Fisher's revenue in any meaningful way, but it shows how the company keeps stacking recurring data and evidence services on top of its core instruments business. The bull case rests on that acquisition engine continuing to convert into real revenue and earnings growth, as it did in 2025. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock. READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In. Disclosure: None. Follow Ins", "date_published": "2026-08-11T21:20:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:8c3210a2efed1a915d0aaa5cca0de5722694e6134cc5a4c6b87354a602e65942", "url": "https://finance.yahoo.com/markets/stocks/articles/idexx-idxx-q2-2026-earnings-162815512.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/idexx-idxx-q2-2026-earnings-162815512.html", "title": "IDEXX (IDXX) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike Erickson Chief Financial Officer - Andrew Emerson Vice President, Investor Relations - John Ravis Full Conference Call Transcript Operator: Good morning, and welcome to the IDEXX Laboratories Second Quarter 2026 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Mike Erickson, President and Chief Executive Officer; Andrew Emerson, Chief Financial Officer; and John Ravis, Vice President, In", "date_published": "2026-08-11T16:28:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IDXX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IDXX", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/f778ff6f-21d3-4bb3-affa-e4d719df5175/"}]}}, {"id": "source:a69cae4db5e2b442f47ba0efd1131089a9b8f487f65c34896986bddbf8f32189", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-analyst-blog-highlights-illumina-145200153.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zacks-analyst-blog-highlights-illumina-145200153.html", "title": "The Zacks Analyst Blog Highlights Illumina, Qnity Electronics and nVent Electric", "content_text": "For Immediate Release Chicago, IL \u2013 August 11, 2026 \u2013 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Illumina ILMN, Qnity Electronics Q and nVent Electric NVT. Here are highlights from Monday's Analyst Blog: More Intervention in Japanese Yen? Global Week Ahead What happens in this Global Week Ahead? No time for a break. Even in the middle of August, there is plenty of market news to watch: \u00b7 There's possi", "date_published": "2026-08-11T14:52:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "ILMN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ILMN", "name": "Illumina, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/30f908cc-747c-41b4-b174-16d8c2b728b4/"}]}}, {"id": "source:5c6a39778f3067627cb7bc3a54e6b94141910a440f639598b5d84d1518ddcad7", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-collaborates-michael-123000003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-collaborates-michael-123000003.html", "title": "Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson\u2019s Precision Medicine", "content_text": "Olink\u2122 Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded the Parkinson's Precision Medicine Initiative (PPMI) proteomic data resource. Scale: Approximately 5,500 research samples were analyzed using Olink technology. Access: The resulting data are available to researchers in PPMI's repository. Purpose: The dataset may help researchers study Parkinson's biology, patient subtypes, disease progression and potential biomarkers. Impact: The resource supports prec", "date_published": "2026-08-11T12:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:849fd66286a023448d721155eb77b3e4932666b084bce0e7349369ce07939314", "url": "https://finance.yahoo.com/healthcare/articles/idexx-expands-catalyst-platform-cardiac-110000498.html", "external_url": "https://finance.yahoo.com/healthcare/articles/idexx-expands-catalyst-platform-cardiac-110000498.html", "title": "IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test", "content_text": "New test brings quantitative cardiac assessment for cats and dogs into everyday workflows WESTBROOK, Maine, August 11, 2026--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst\u2122 proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cat", "date_published": "2026-08-11T11:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "IDXX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IDXX", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/f778ff6f-21d3-4bb3-affa-e4d719df5175/"}]}}, {"id": "source:087d578d3f75d830d50d54bbb4f31de98eb6f9576d94fb132b7fae0ab08fa04b", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "external_url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "content_text": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued investment in cell and gene therapy research, and technological advances in intracellular delivery systems. Non-Viral Transfection Reagents Market Growth and Trends The expanding development and commercialization of gene therapies, mRNA therapeutics, RNA interference drugs, DNA vaccines, and gene-editing technologies are increasing demand for efficient transfection reagents and systems. Regulatory approvals for nucleic acid-based therapies have further reinforced the clinical and commercial potential of this therapeutic class. Industry stakeholders are increasingly adopting non-viral gene delivery technologies in response to the limitations associated with viral vectors, including immunogenicity, cytotoxicity, high manufacturing costs, restricted cargo capacity, and complex production requirements. Non-viral transfection platforms can offer greater scalability, manufacturing flexibility, and suitability for research and therapeutic workflows. Advances in lipid-based, polymer-based, nanoparticle-based, and electroporation systems are improving intracellular uptake, delivery precision, cell viability, and compatibility across diverse cell types. Nanotechnology-enabled carriers are also supporting targeted delivery through multifunctional designs that incorporate therapeutic payloads and targeting ligands. Products leveraging these technologies include jetOPTIMUS and PolyMag. Key Market Drivers and Challenges Major growth drivers include the increasing prevalence of chronic diseases, expanding pharmaceutical and biotechnology research expenditure, growing adoption of CRISPR-Cas9 and other gene-editing platforms, and rising demand for advanced cell and gene therapies. The need for scalable delivery technologies across research, process development, and clinical manufacturing is expected to create additional opportunities for non-viral transfection reagent developers. Despite a favorable outlook, the market faces challenges related to transfection efficiency in primary and hard-to-transfect cells. Limited intracellular uptake, genetic material stability, transient gene expression, reagent-related cytotoxicity, and variable performance across cell lines may also affect adoption. Additional barriers include the absence of standardized protocols, substantial optimization costs, regulatory complexity, and competition from emerging delivery platforms. Story Continues Market Segmentation Highlights The non-viral transfection reagents market is segmented by transfection method, application, end-user, and geography. Method: Chemical methods, physical methods, and other methods Application: Research applications and clinical applications End-user: Academic and research institutions, pharmaceutical and biotechnology companies, contract manufacturers, and other end-users Geography: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa Chemical methods account for nearly 60% of the overall non-viral transfection reagents and equipment market. This position is supported by the broad adoption of chemical reagents and non-viral vectors in primary cell transfection and gene therapy research. Physical methods are expected to register a comparatively higher growth rate through 2035, supported by advances in electroporation technologies that can provide shorter processing times, lower toxicity, and broad compatibility with nucleic acid", "date_published": "2026-08-11T08:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:20e36330147524c7cb192fdea0f1db3c871b686ef1c9f570661661fe8c4ad2e9", "url": "https://www.nasdaq.com/articles/mettler-toledo-director-sold-600000-stock-heres-what-investors-should-know", "external_url": "https://www.nasdaq.com/articles/mettler-toledo-director-sold-600000-stock-heres-what-investors-should-know", "title": "A Mettler-Toledo Director Sold $600,000 in Stock. Here's What Investors Should Know", "content_text": "Key Points The transaction involved the sale of 415 shares at $1,444.62 per share, representing an estimated value of about $599,517 on August 3. The disposition resulted from the immediate sale of shares acquired through the exercise of 415 stock options at a strike price of $397.95. Salice continues to maintain significant equity exposure via indirect holdings totaling 52,492 shares held through two separate investment entities.10 stocks we like better than Mettler-Toledo International \u203a Thomas P. Salice, a director at Mettler-Toledo International Inc.(NYSE:MTD), sold 415 shares of common st", "date_published": "2026-08-10T23:09:31+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Capital return", "MTD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MTD", "name": "Mettler-Toledo International Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/45b02b93-e39e-404d-a31a-c83ea8212fc2/"}]}}, {"id": "source:8c9fdf6a116d009df66e3cf03a87a76899ea38b0b6aad12695b434abc2cc15e8", "url": "https://www.nasdaq.com/articles/mettler-toledos-cfo-cashed-options-after-strong-quarter-heres-what-know", "external_url": "https://www.nasdaq.com/articles/mettler-toledos-cfo-cashed-options-after-strong-quarter-heres-what-know", "title": "Mettler-Toledo's CFO Cashed In Options After a Strong Quarter. Here's What to Know", "content_text": "Key Points The disposition involved 2,240 shares at $1,432 per share, totaling about $3.2 million on August 3, 2026. The transaction was structured as a same-day exercise-and-sell involving 2,240 stock options at an exercise price of $595.31. Following the sale, the insider maintains direct ownership of 5,579 shares with a market value of $8.1 million as of the transaction date.10 stocks we like better than Mettler-Toledo International \u203a Shawn Vadala, the chief financial officer of Mettler-Toledo International Inc.(NYSE:MTD), executed a sale of 2,240 shares on August 3, according to an SEC For", "date_published": "2026-08-10T23:02:03+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MTD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MTD", "name": "Mettler-Toledo International Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/45b02b93-e39e-404d-a31a-c83ea8212fc2/"}]}}, {"id": "source:c27320e8ca02985c9f1c86b98dd29b4b9a258173202b95b8fabee03750fbf62c", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-gain-afternoon-195804577.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-gain-afternoon-195804577.html", "title": "Sector Update: Healthcare Stocks Gain Late Afternoon", "content_text": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-10T19:58:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:a154841a20179ab408369874e9631ab5bb694429f8d159cb1e5aa9d93a3b4a48", "url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-thermo-fisher-scientific-191508215.html", "external_url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-thermo-fisher-scientific-191508215.html", "title": "How Investors Are Reacting To Thermo Fisher Scientific (TMO) New FDA-Cleared Multiple Myeloma Platform", "content_text": "In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for clinical laboratories. By pairing these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S, Thermo Fisher is deepening its role in linking high-complexity diagnostics with streamlined lab workflows and more standardized ", "date_published": "2026-08-10T19:15:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:6038f22aad4fd393cbbf01648401cd7f87962e69d81d7f61d81eef7db7c5ad36", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-174031450.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-174031450.html", "title": "Sector Update: Healthcare Stocks Rise in Afternoon Trading", "content_text": "Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-10T17:40:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:309a29f5c028e2baf45de118523760972e80d1f8e0c912e8ede47a96913c6a6c", "url": "https://finance.yahoo.com/markets/stocks/articles/beat-market-zacks-aveanna-factset-123400629.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/beat-market-zacks-aveanna-factset-123400629.html", "title": "Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus", "content_text": "Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. economic outlook, expectations for a supportive Federal Reserve policy environment and easing concerns about inflation. Strong corporate earnings also helped reinforce confidence in the market's growth prospects. Technology and growth-oriented sectors led the advance, boosting the Nasdaq, while broader participation supported gains in the S&P 500 and Dow. Falling Treasury yields and expectations of potential interest-rate cuts further encouraged investors to increase exposure to equities, lifting major indexes to stronger weekly finishes. Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market. As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action. Here are some of our key achievements: Aveanna and Surgery Partners Surge Following Zacks Rank Upgrade Shares of Aveanna Healthcare Holdings Inc. AVAH have gained 32.4% (versus the S&P 500's 2.2% increase) since it was upgraded to a Zacks Rank #2 (Buy) on June 1. Another stock, Surgery Partners, Inc. SGRY, which was upgraded to a Zacks Rank #1 (Strong Buy) on June 1, has returned 16.2% since then. A portfolio of Zacks # 1 Rank (Strong Buy) stocks has outperformed the S&P 500 index by 5.7 percentage points this year. Through July 6th this year, the Zacks # 1 Rank portfolio returned +15.3%, which compares to a +9.7% gain for the S&P 500 index and a +12.6% gain for the equal-weight version of the index in the same time period. Since its inception in 1988, this portfolio of Zacks # 1 Rank stocks has outperformed the market by 12.4 percentage points. The average annual return for this portfolio of Zacks # 1 Rank stocks since inception in 1988 was +23.9% through July 6th, which compared to a +11.6% gain for the S&P 500 index and a +11.4% gain for the equal-weight version of the index. You can see the complete list of today's Zacks Rank #1 stocks here >>> Check Aveanna's historical EPS and Sales here>>> Check Surgery Partner's historical EPS and Sales here>>>Zacks Investment Research Image Source: Zacks Investment Research Zacks Recommendation Upgrades TWFG and Heico Story Continues Shares of TWFG, Inc. TWFG and Heico Corporation HEI have surged 46.3% (versus the S&P 500's 4.8% rise) and 13.6% (versus the S&P 500's 4.6% rise), since their Zacks Recommendation was upgraded to Outperform on June 8 and June 9, respectively. While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions. The Zacks Recommendation classifies stocks into three groups \u2014 Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model. To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>> Zacks Focus List Stocks Shopify, CACI Shoot Up Shares of Shopify Inc. SHOP, which belongs to the Zacks Focus List, have gained 37.3% over the past 12 weeks. The stock was added to the Focus List on September 6, 2022. Another Focus-List holding, CACI International CACI, which was added to the list on December 2, 2015, has returned 34% over the past 12 weeks. The S&P 500 has ", "date_published": "2026-08-10T12:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}]}}, {"id": "source:cf5876587718bd1c845e6d6d2f5587edbccd20aa96ef6b42f35f990578eb1131", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-tmo-vs-danaher-000131616.html", "external_url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-tmo-vs-danaher-000131616.html", "title": "Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?", "content_text": "Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher's (NYSE:DHR) recovery remains more uneven. Which stock looks better positioned for the next phase of the life sciences rebound?Top Long-Term Biotechnology Stocks to Buy Thermo Fisher Scientific Inc. (NYSE:TMO) recently announced strong fiscal Q2 2026 results, with revenue growing 10% to $11.99 billion, GAAP diluted EPS rising 9% to $4.68, and adjusted EPS growing 13% to $6.03. Danaher Corporation's (NYSE:DHR) second-quarter results, on the other hand, were marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit adjusted EPS growth. Bull Case Thermo Fisher Scientific Inc.'s (NYSE:TMO) quarter suggests that the recovery in life sciences spending is becoming increasingly broad-based. Management highlighted improving customer activity across pharmaceutical and biotechnology markets, while multiple operating segments returned to healthy growth. That is encouraging because recoveries driven by several business lines tend to be more durable than those supported by a single segment. Thermo Fisher Scientific Inc.'s (NYSE:TMO) Life Sciences Solutions segment reinforced the recovery narrative. Reported revenue climbed 13% year over year, while organic revenue rose 3%, led by continued strength in the high-margin bioproduction business. Healthy demand in this segment is particularly encouraging because it reflects ongoing investments and supports management's view that end-market conditions continue to improve. Perhaps the biggest positive from the quarter was the recovery in Analytical Instruments, a business that had faced weak demand for nearly two years as biotechnology funding slowed. Its return to growth provides another indication that laboratory spending is beginning to normalize. While one quarter does not establish a trend, sustained improvement in this segment would strengthen the case that the industry's post-pandemic downturn is easing. Thermo Fisher Scientific Inc. (NYSE:TMO) also continued investing in product innovation through launches such as the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers. Continued innovation has historically helped the company defend its competitive position in premium analytical instruments, which could become increasingly important as customer spending gradually improves. Story Continues Danaher Corporation's (NYSE:DHR) results also pointed to improving fundamentals, although the recovery appears less mature than Thermo Fisher's (NYSE:TMO). The company's Life Sciences business delivered its strongest performance in several years, while bioprocessing orders increased at a mid-teens rate despite reported revenue being affected by customer project timing. Strong orders matter because they often precede future revenue recognition, suggesting underlying customer demand may be healthier than current reported sales imply. Management also disclosed that just over $100 million of revenue shifted into next year because of customer project timing. If those projects proceed as expected, that revenue has been deferred rather than lost, potentially providing an additional tailwind in future quarters. Danaher Corporation (NYSE:DHR) further noted that academic and government markets have largely stabilized. Although it stopped short of describing those markets as fully recovered, stabilization removes one of the major headwinds that weighed on life sciences spending over the past two years. Bear Case Despite the encouraging results, investors should avoid assuming that the recovery will mirror t", "date_published": "2026-08-10T00:01:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TMO", "DHR"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMO", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/028894a2-fea3-4629-861d-03e119aeecfd/"}, {"symbol": "DHR", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/fe21a17c-6fdf-42c3-8e76-19bd3a234024/"}]}}, {"id": "source:a78ba7b2c2442b2f646b458fa3882677e80c447a8ad77003f7781ec1e02c049a", "url": "https://finance.yahoo.com/markets/stocks/articles/3-stocks-under-50-open-211722201.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/3-stocks-under-50-open-211722201.html", "title": "3 Stocks Under $50 with Open Questions", "content_text": "3 Stocks Under $50 with Open Questions Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market. Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. Keeping that in mind, here are three stocks under $50 to pass on and some alternatives you should look into instead. Oxford I", "date_published": "2026-08-09T21:17:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NEO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NEO", "name": "NeoGenomics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a0a5afdf-76c4-4d2c-ae9e-7721ea8c1f87/"}]}}, {"id": "source:e8b3705a8dfd1a6a26a224a42ac2305fb9383f131c45d29fd252a6271d54e80a", "url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-iqvia-holdings-iqv-151122324.html", "external_url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-iqvia-holdings-iqv-151122324.html", "title": "How Investors Are Reacting To IQVIA Holdings (IQV) Cardiac Gene Therapy Push And Higher 2026 Revenue Outlook", "content_text": "In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA's global clinical and commercialization infrastructure with Medera's Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA's second-quarter results, raised full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion, and continued share repurchases. The partnership's focus on AAV-based cardiac gene therapies and Novoheart's mini-Heart platform under the FDA Modernization Act 2.0 highlights IQVIA's deeper push into cutting-edg", "date_published": "2026-08-09T15:11:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IQV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IQV", "name": "IQVIA Holdings Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1923edc2-ce9d-4226-9982-745e38a79bad/"}]}}, {"id": "source:1ee570f659f04f24363b3ee33967013b02cb7094444753a51889cd67b94881a1", "url": "https://finance.yahoo.com/healthcare/articles/waters-wat-launches-xevo-tq-130828943.html", "external_url": "https://finance.yahoo.com/healthcare/articles/waters-wat-launches-xevo-tq-130828943.html", "title": "Waters (WAT) Launches Xevo TQ Absolute XR IVD For Clinical Labs", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Waters (NYSE: WAT) introduced the Xevo TQ Absolute XR IVD Mass Spectrometer, a new clinical laboratory system with high analytical sensitivity and robustness. The instrument targets critical clinical applications, including hormone testing and toxicology workflows. The launch expands Waters' clinical diagnostics product lineup at a time when demand for precise mass spectrometry tools in healthcare remains a key focus for laboratories. Consider exploring ", "date_published": "2026-08-08T13:08:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "WAT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "WAT", "name": "Waters Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/b7350fb0-16e4-4c51-b53b-3a26a71ff1fa/"}]}}, {"id": "source:80358014ff6ec13ae3e96352e745e517a9a9350c6eb13aa80134d39b31b42cba", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE9kTG1mRzhYcGNBX21rb2hwYnJRX0I5WGxsVkk4X2NMMkd1eGFUYjlYVVh6TWpkTHpSNG9CVHVNM0JmN2pyYTBXU2p5M3k5ZWo1MHZuTDE1aEU5TEZXbzhkYVp3WFY?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE9kTG1mRzhYcGNBX21rb2hwYnJRX0I5WGxsVkk4X2NMMkd1eGFUYjlYVVh6TWpkTHpSNG9CVHVNM0JmN2pyYTBXU2p5M3k5ZWo1MHZuTDE1aEU5TEZXbzhkYVp3WFY?oc=5", "title": "Noticias de acciones de Fulgent Genetics Inc (FLGT)", "content_text": "Noticias de acciones de Fulgent Genetics Inc (FLGT)", "date_published": "2026-08-07T18:55:35+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "FLGT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FLGT", "name": "Fulgent Genetics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/aa806797-68a3-4a8b-afb6-c603ea0f9bf0/"}]}}, {"id": "source:140543424190b6fad1d8f90ea169e7ca8300ae4d71c3bdaf62de70b9a6bd78e5", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQdjBiSXlSbHVOSERNZ3I0MmhtMWRoOHRCQmxEWFhJc2ktMTE5TGRJLW9mZnYtQVJ0ZEVLSVRqa0ZWeDQ4eU9jQ29iR3BYTHBaUUZfdDVpdjNWOGdNbmpfbFhnNVFjc1ZVN2prSl9mRXVMUlhTNVZXVWMxRFFuMEhXRXNyblVQaHBNUFVBNHVBN0lhVGw0WnV2RmdKVFBrT2xfc09NOG95RjRnMTJLZmJtT1Vpb1FudlFsWVVIeHlaY1VRQi1CLUo4TklZZ1BVbXB4MGpLaEJORlNPM3U2SDNlbVRENm1Md2RPZVE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQdjBiSXlSbHVOSERNZ3I0MmhtMWRoOHRCQmxEWFhJc2ktMTE5TGRJLW9mZnYtQVJ0ZEVLSVRqa0ZWeDQ4eU9jQ29iR3BYTHBaUUZfdDVpdjNWOGdNbmpfbFhnNVFjc1ZVN2prSl9mRXVMUlhTNVZXVWMxRFFuMEhXRXNyblVQaHBNUFVBNHVBN0lhVGw0WnV2RmdKVFBrT2xfc09NOG95RjRnMTJLZmJtT1Vpb1FudlFsWVVIeHlaY1VRQi1CLUo4TklZZ1BVbXB4MGpLaEJORlNPM3U2SDNlbVRENm1Md2RPZVE?oc=5", "title": "Resultados trimestrales: NeoGenomics supera las previsiones con un beneficio por acci\u00f3n ajustado de 0,05 USD en el segundo trimestre", "content_text": "Resultados trimestrales: NeoGenomics supera las previsiones con un beneficio por acci\u00f3n ajustado de 0,05 USD en el segundo trimestre", "date_published": "2026-07-28T21:05:50+00:00", "authors": [{"name": "MarketScreener Espa\u00f1a"}], "tags": ["Market update", "NEO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NEO", "name": "NeoGenomics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/a0a5afdf-76c4-4d2c-ae9e-7721ea8c1f87/"}]}}]}